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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a potentially curative therapy for many malignant
and nonmalignant hematological diseases. The curative
effect of allo-HSCT results from both the chemotherapy/
radiation in the conditioning regimen and the donor
T-mediated graft-versus-host (GVH) response against the
malignancy known as a graft-versus-leukemia (GVL) effect.
In most cases, the GVH response is not limited against the
malignant cells but is also mediated against host epithelial
cells, causing graft-versus-host disease (GVHD).
The safety and effectiveness of allogeneic transplants has
increased substantially over the last several years. Despite
this progress, GVHD and relapse remain the biggest hurdles
for a more widespread and effective use of this potent
therapy. Experimental data from recent years have provided
deeper and better insights into the process of GVH responses.
Emerging data have reﬁned our understanding of the role of
antigen-presenting cells (APC) in GVHD. Novel molecular
targets have been identiﬁed in donor T cell subsets and host
nonhematopoietic cells that can potentially be exploited for
mitigating GVHD and to better harness GVL.
The role of various cytokines in GVHD continues to be
explored. This work has led to improved understanding of
potential causes for tissue speciﬁcity of GVHD. The role of
host and donor microbiome in regulating GVH responses has
been a subject of intense focus as well. Notable advances
have been made in deﬁning various other aspects of GVH
responses, but these go beyond the scope of this brief review.
Herein we focus on three speciﬁc aspects of GVH responses,
namely 1) the evolving role of hematopoietic APCs as the
regulators of GVHD, 2) novel strategies for enhancing GVL
responses, and 3) the recently identiﬁed molecular targets
for mitigating GVH responses.HEMATOPOIETIC APCS: EMERGING REGULATORS
OF GVHD
GVHD manifests in two forms, acute and chronic, which
differ in time of presentation (early versus late) and aspects
of pathophysiology (eg, more prominent ﬁbrosis in chronic
GVHD). GVHD is T cell mediated and directed against host
major or minor histocompatibility antigens. For effector T cell
activation and differentiation, APCs are required. Although
the effectors of GVHD are donor-derived T cells, both host
and donor APCs can present host antigens to the donorFinancial disclosure: See Acknowledgment on page S13.
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cells available to prime donor T cells. However, as host
hematopoietic APCs are reduced and donor APCs emerge,
recipients are chimeric for donor- and host-derived APCs for
a period of time before the point when donor APCs only are
present. Both donor and host APCs have been shown to
contribute to the initiation and maintenance of GVHD;
however, the relative contribution of these APC populations,
and speciﬁc APC subsets, is only now being realized through
the development of novel models of alloantigen presentation
and transgenic/knockout mice and antibodies that permit
the conditional depletion of speciﬁc APC subsets. Antigen
presentation is typically deﬁned as the presentation of
recipient-derived peptide in the major histocompatibility
complex (MHC), resulting in the stimulation of MHC-
matched donor T cells. This is because the requirement for
peptide presentation in MHC disparate systems and the
contribution thereof to GVHD remains unclear. As such,
many attributes ascribed to APCs may be independent of
antigen presentation. APCs may also act via secretion of
cytokines or the relative expression of costimulatory mole-
cules rather than the function of presenting antigen.
Current paradigms of antigen presentation and the
induction of GVHD are based on the pivotal studies of
Shlomchik et al., which demonstrated in CD8-dependent
models that host hematopoietic-derived APCs were abso-
lutely required for the induction of GVHD and that donor APC
could amplify this effect [1,2]. A study by the Teshima group
further established that antigen presentation by hemato-
poietic cells was sufﬁcient to induce GVHD and that
expression of antigens on nonhematopoietic target tissue is
not required (cognate interactions) because the GVHD
effectors in CD4-dependent GVHD in particular are soluble
cytokines [3]. These studies have generated the notion that
hematopoietic APCs are essential for the induction of acute
GVHD, and as dendritic cells (DC) are appreciated as themost
efﬁcient APC population, it has largely been inferred that DC
represent the critical APC population in the pathogenesis of
GVHD. However, emerging evidence questions the relative
capacity of hematopoietic APC, and particularly DC, to invoke
GVHD, particularly early after bone marrow transplantation
(BMT). In this regard, recent studies have demonstrated
antigen presentation by host nonhematopoietic cells to be
sufﬁcient to induce lethal acute GVHD [4,5] and overall point
to a largely immunomodulatory role for the various hema-
topoietic APC subsets, in particular DC. These issues become
important given the recent focus on targeting APC pop-
ulations (especially DC) for depletion as a means to diminish
GVHD [6,7]. It is thus imperative to clarify the relative
contribution of host versus donor and hematopoietic versus
nonhematopoietic antigen presentation to GVHD for theTransplantation.
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summarized below that delineate the contribution of non-
hematopoietic antigen presentation and speciﬁc hemato-
poietic APC subsets to GVHD pathogenesis.
Recipient Hematopoietic APCs
DCs, including conventional DCs (cDCs) and plasmacytoid
DCs (pDCs), are widely recognized to exhibit both immu-
nostimulatory and immunoregulatory functions. In 2002
a correlative study demonstrating that residual activated
host cDCs were present at the time of donor T cell activation
was instrumental in consolidating the dogma that host DCs
are the key immunostimulatory APCs responsible for
promoting GVHD early after transplantation [8]. However,
recent studies in both MHC class II- and class I-dependent
models using induced or constitutive depletion of CD11cþ
cDCs have unexpectedly failed to demonstrate a requirement
for recipient cDCs in the induction of acute GVHD [4,9].
Indeed, in the absence of recipient DCs, alloreactive T effec-
torecell expansion was signiﬁcantly exaggerated, suggesting
cDCs may in fact regulate alloreactivity via the induction of
donor T cell death [4].
Likewise, current data do not support a role for recipient
pDCs in the induction of GVHD. Although adoptive transfer
studies have demonstrated the capacity of recipient pDCs to
prime donor T cells and induce GVHD [10], this population
has been shown to be exquisitely radiosensitive and is
depleted after total body irradiation before transplantation.
Thus, pDCs are unlikely to contribute to GVHD pathogenesis
[11,12]. Further in support of this conclusion is a recent study
in which recipient pDCs were depleted without a resultant
effect on the induction of GVHD [9]. Although actual antigen
presentation by recipient macrophages or B cells has not as
yet been formally assessed, depletion studies demonstrate
that these recipient APC populations are not required for the
induction of GVHD but that their removal can markedly
exacerbate GVHD [9,13-16]. The depletion of resident tissue
macrophages in transplant recipients using antibodies
directed against CSF1R resulted in hyperacute GVHD with
exaggerated donor T cell activation, suggesting a role for
these populations in inducing peripheral tolerance [13,14].
Furthermore, recipient macrophage-mediated clearance of
apoptotic T cells was indicated as a potential regulatory
mechanism [13]. In contrast, regulation of GHVD by recipient
B cells was shown to bemediated by interleukin-10 secretion
[16]. Thus, absence of any single subset of host hematopoietic
APCs exacerbates GVHD when all other subsets are intact.
Recipient Nonhematopoietic APCs
BMT conditioning and GVHD itself is associated with the
induction of MHC on the endothelial and epithelial cells of
target tissues including skin [17,18] and gut with acquisition
of functional antigen-presenting activity [19,20]. Thus, it is
possible that nonhematopoietic APCs can induce GVHD in
isolation of hematopoietically derived APC. Two recent
studies have examined this. First, Koyama et al. demon-
strated that donor APCs had only a limited capacity to
induce MHC class IIedependent GVHD lethality and most of
this effect resided in the recipient APC pool [4]. Surprisingly,
the nonhematopoietic APCs were more effective at inducing
GVHD lethality than hematopoietic APCs. In particular, large
numbers of MHC class IIepositive nonhematopoietic ﬁbro-
blasts were present in the small bowel, and intestinal
epithelium also expressed MHC class II after BMT. Interest-
ingly, the inﬂammatory environment after conditioning wassufﬁcient to allow T cell activation in lymph nodes inde-
pendent of antigen such that they rapidly acquired memory
phenotype and gained access to target tissue (and MHC
antigen). The second study demonstrated that radioresistant
(putatively nonhematopoietic) cells can also invoke lethal
MHC class Iedependent GVHD [5], although consistent with
the original Shlomchik et al. study [2], hematopoietic APCs
were more potent in induction of GVHD. Thus, it appears
that GVHD and particularly MHC class IIedependent GVHD
can be elicited in isolation by nonhematopoietic APCs. The
exact nature of these nonhematopoietic tissue APCs, the
pathways they use for presentation, and the factors
controlling presentation by these cells remains to be
elucidated.
Donor APCs
Because hematopoietic APCs are derived from hemato-
poietic stem cells, donor APCs are all hematopoietic derived
and indirectly present antigen to CD4þ T cells. Depletion
studies have demonstrated that the only donor APCs capable
of presenting alloantigen after BMT are cDCs [21]. Interest-
ingly, MHC class IIedependent antigen presentation by the
same donor cDCs is corrupted by GVHD, and this appears to
contribute to GVHD-induced immune suppression [22].
Given their role in maintaining regulatory T cell homeostasis,
this corruption of donor DC function during acute GVHD is
likely to contribute to chronic GVHD development and the
dramatic defects in immunity seen in this condition. In
regards to cross-presentation (presentation of exogenous
alloantigen within donor MHC class I), donor cDCs are again
the critical APCs, and this process appears controlled by
CD40 and type I interferons [23]. Although donor macro-
phages do not appear to actively present alloantigen after
BMT [21], theymay be involved in some of the late ﬁbrogenic
manifestations of chronic GVHD [24]. Furthermore, whereas
donor B cells do not present antigen themselves, they appear
to regulate antigen presentation by cDCs during acute GVHD
[21], which may reﬂect intrinsic regulatory function in
subpopulations of these cells (ie, regulatory B cells). In
contrast to a potential regulatory role, B cells can also
contribute to ﬁbrogenic manifestations of chronic GVHD in
lung and liver via the induction of autoantibodies in amurine
model [25]. Several human studies further suggest a poten-
tial pathological role for B cells in chronic GVHD in light of
likely clinical improvement in chronic GVHD after rituximab
therapy [26,27]. Similarly, although pDCs do not appear to
actively present alloantigen, their differentiation is corrupted
during GVHD, resulting in the accumulation of early
precursors that attenuate GVHD [11]. It also appears that
pDCs may alter donor T cell differentiation, particularly in
regard to the promotion of regulatory T cell expansion, an
effect mediated by indoleamine 2,3-dioxygenase [28].
Taken together, these data clearly highlight an emerging
concept that the predominant role of the hematopoietic APCs
of either recipient or donor origin is in the regulation of
GVHD (particularly in acute GVHD). Thus, simple depletion of
any of these populations, in isolation or combination, early
post-transplantation is unlikely to provide clinical beneﬁt
and has in fact the potential to exacerbate acute GVHD.
Conversely, the in vivo modulation of these APC populations
via cytokine administration or adoptive cell therapy may
effectively attenuate GVHD. Strategically, future efforts to
disrupt antigen presentation to attenuate GVHD will need to
focus on targeting components of the molecular pathways
underpinning this process.
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Alloreactive T cells delivered with allogeneic hematopoi-
etic stem cell grafts have been the most widely applied form
of adoptive T cell therapy for cancer. In MHC-matched
transplants, which are the most common, alloreactive
T cells recognize the peptide products of polymorphic genes
that distinguish hosts from donors, called minor histocom-
patibility antigens (miHAs). However, despite its efﬁcacy,
allo-HSCT and the GVL effect have limitations yet to be
substantially addressed in the clinic. The ﬁrst is that GVL is
closely linked with GVHD. That this has broadly proven to be
the case is not surprising given that alloreactive T cells can
recognize host miHAs, whether they are on hematopoietic
cells, neoplastic cells, or nonmalignant host tissues.
Successful approaches to minimize GVHD while maintaining
GVL will require methods to engineer T cells with antigen
speciﬁcity or to narrow the range of effector functions and
locations whereby alloreactive T cells can still kill neoplastic
cells but lack or are diminished in mediators of broader
tissue damage. Alternatively or in addition, strategies that
protect normal tissues from T cells or that augment their
regeneration after T cell attack may increase the therapeutic
window of polyclonal alloimmune T cells. Mouse models are
ideal for such studies because a wide array of gene-modiﬁed
mice and reagents can be applied.
After GVHD, the second major limitation of allo-HSCT is
leukemia/lymphoma relapse, which according to Center for
International Blood and Marrow Transplant Research anal-
yses is the single leading cause of death after allo-HSCT. The
failure of allo-HSCT to cure a givenmalignancymust relate to
features of the alloimmune response and/or to the sensitivity
of leukemias to appropriately targeted T cells. In some anal-
yses the strength of the alloimmune response asmeasured by
severity of GVHD is inversely related to the risk of relapse,
which suggests that a more leukemia/lymphomaetargeted
T cell response could have a clinical beneﬁt. This is apparent
from numerous studies in which donor T cell numbers were
titrated against a ﬁxed leukemia dose. More recently, we
published that donor vaccination against a single miHA
results in a substantially larger anti-miHA response and
improved GVL effect [29]. We vaccinated C3H.SW mice
(H60; H-2b) against an immunodominant Kb-restricted
epitope derived from H60 (LTFNYRNL). This created a stable
population of mostly central memory CD8 cells in the donor.
B6.H60 (H60þ; H-2b) mice were radiated and reconstituted
with C3H.SW bone marrow and puriﬁed memory CD8 cells
from vaccinated donors or memory or naïve CD8 cells from
unvaccinated donors. Memory CD8 cells from vaccinated
donors were far more potent mediators of GVL than were
naïve CD8 cells or memory cells from unvaccinated mice.
H60-reactive CD8 cells underwent dramatic expansion post-
transplantation in a CD4-independent fashion. GVHD was
minimal both because so few donor CD8 cells were infused
and because the response was focused on H60, which is
largely restricted to host hematopoietic cells.
Relapse risk is not equivalent for various malignancies but
rather tracks with the type of leukemia/lymphoma. As
patients overall are likely to develop similar alloimmunity
regardless of leukemia type, this suggests speciﬁc features of
hematopoietic malignancies that render them more or less
sensitive toTcell immunotherapy. With this idea in mind, we
focused on the end effector mechanisms whereby leukemias
are killed by alloreactive T cells, reasoning that it is in this
ﬁnal step that GVL-sensitive and GVL-resistant neoplasms
may differ.For this purpose, our group used mouse models of GVL-
sensitive and GVL-resistant leukemias induced by retroviral
gene transfer [29-33]. As a model of GVL-sensitive leukemia
we used retroviral transfer of bcr-abl, which recapitulates
key features of chronic phase chronicmyelogenous leukemia.
As a GVL-resistant blast crisis model, we transfer both bcr-abl
and the NUP98-HOXA9 fusion. Because these leukemias
are induced by retrovirus, we have been able to create a
wide panel of gene-deﬁcient leukemias to study T cell end
effector mechanisms, including the role of cognate T cell
receptoreMHC interactions, the importance of speciﬁc killing
mechanisms (or rather their surprising redundancy), and the
role of PD ligands.
There are several key ﬁndings from these studies. First,
both CD4 and CD8 cells must make cognate T cell recep-
toreMHC interactions with leukemia targets. Second, ﬁnal
killing mechanisms are redundant in that GVL effect was
unaffected when leukemias were deﬁcient in Fas, TRAILR, Fas
and TRAILR, or TNFR1/R2 or when T cells were deﬁcient in
perforin. In contrast, leukemias must express ICAM-1 for
effective GVL. Finally, PD-L1 and PD-L2 on chronic phase
chronic myelogenous leukemia cells inhibited GVL; however,
we could not ﬁnd a role for PD ligands in inhibiting GVL effect
against blast crisis chronic myelogenous leukemia despite
their being expressed. In our oral presentation we describe
new work demonstrating how donor T cells ﬁrst “condition”
and then kill leukemia stem cells.NOVEL MOLECULAR TARGETS IN T CELLS THAT
MODULATE GVH RESPONSES
The drugs that are most commonly used in clinical prac-
tice predominantly target donor T cells. They include direct
depletion of T cells with steroids, cyclophosphamide, or with
various antibodies directed toward T cells. Additionally,
T cells are targeted via inhibition of calcineurin pathway
(cyclosporine A or tacrolimus) or the mTOR pathway (rapa-
mycin). In recent years several additional pathways that are
critical for donor T effector and regulatory T cells have been
identiﬁed to play a key role in regulating GVH responses.
However, describing all of them is beyond the scope of this
brief review. We focus only on some of the intracellular
molecular targets in T cells recently recognized as being
critical for regulating alloreactivity.Epigenetic Targeting in Donor T Cells
Histone acetylation and methylation along with DNA
methylation are critical for modulating the epigenetic regu-
lation in all cells. Experimental data have shown that tar-
geting histone acetylation with agents that block several
histone deacetylases simultaneously can regulate GVHD by
affecting various immune cell subsets, including donor T
regulatory cells [34,35]. The clinical availability of pane
histone deacetylase inhibitors has led to translation of this
strategy into a proof of concept clinical trial, the results of
which so far appear to be very encouraging [34]. Global
inhibition of histone methylation with DZnep [36] reduced
experimental GVHD by promoting apoptosis of allo-activated
T effector cells. In addition, DNA hypomethylating agents
have also been shown to reduce GVHD inmice through direct
effects on donor regulatory T cells [37]. The molecular
pathways that are critical for the overall impact of globally
targeting epigenetic mechanisms are likely to be complex,
and much remains to be understood. However, the avail-
ability and known toxicity proﬁles of some of these agents
K.P. MacDonald et al. / Biol Blood Marrow Transplant 19 (2013) S10eS14 S13provide impetus for studying these approaches in carefully
designed clinical trials.
Targeting Notch Signals in Donor T Cells
Signaling initiated by Notch activation is implicated
in several fundamental cellular processes such as differen-
tiation, survival, and homeostasis. The impact of lack of
signaling from activation of Notch, exclusively on donor
T cells, was recently shown to mitigate GVHD in experi-
mental models [38]. The clinical availability of g-secretase
(facilitates Notch activation by its proteolytic cleavage)
inhibitors and potential availability of speciﬁc Notch
receptor/ligand blockers suggest that these agents, if safe,
could be studied in humans to prevent or treat GVHD [39].
However, the role of several speciﬁc Notch receptors or many
of their ligands and their sources in regulating exclusively
donor T cell responses remains to be better understood.
Targeting Mitochondrial ATPase
mTOR inhibitors affect T cell metabolism and thus
contribute to their T cell modulatory effects [40]. A recent
article identiﬁed another putative metabolic target, mito-
chondrial APTase, as a potential objective for regulating T cell
responses [41]. Bz-423, a small-molecule inhibitor of the
mitochondrial F(1)F(0) adenosine triphosphate synthase
(F(1)F(0)-ATPase), selectively increased superoxide and
induced the apoptosis of alloreactive T cells, which arrested
GVHD in murine models [41].
Targeting the Proteasome
Based on several recent experimental observations, the
proteasome inhibitor bortezomib was used and suggested to
have activity in regulating clinical GVHD [42,43]. Proteasome
inhibition, in addition to affecting various other immune
cells, has been shown to directly induce apoptosis of allor-
eactive T cells. Although all critical molecular mechanisms of
global proteasome inhibition on GVHD remain to be deci-
phered, the development of several novel proteasome
inhibitors with better therapeutic and safety proﬁle suggest
that this pathway can potentially be exploited to mitigate
clinical GVHD [44].
Targeting Protein Kinase C Theta
Elegant studies have shown that protein kinase C theta is
critical for activation and survival of naïve T cells while also
modulating regulatory T cell potency at the level of immu-
nological synapse [45]. Data have shown that targeting
protein kinase C theta in donor T cells reduced GVHD in
murine models [46]. The availability of a small molecule that
inhibits protein kinase C theta suggests that this could be
a potential strategy for testing in humans [45].
MicroRNAs
MicroRNAs are noncoding RNAs that are emerging as
potent regulators of immune responses [47]. MicroRNA-155
(miR-155) plays an important T cell intrinsic role in regu-
lating immune responses in addition to having distinct
effects in other immune cells [47]. A recent study showed
that miR-155 is up-regulated in allo-stimulated T cells [48].
The miR-155edeﬁcient T cells, when used as donor T cells,
induced less severe GVHD than WT controls. Interestingly,
miR-155 was also found to be up-regulated in intestinal
biopsies from GVHD patients. The role of noncoding RNAs
in regulating alloeT cell responses offers a potential for
a better and more reﬁned understanding of donor T cellresponses. The availability of technology to generate oligo-
nucleotides that can target microRNAs in vivo and be deliv-
erable as well in humans points to potential development
of speciﬁc targeting of microRNAs as new approach for
mitigating GVHD.Targeting JAK-STAT Pathways
The role of speciﬁc STATs in regulating donor T cell
subsets has illuminated a potential role for the proteins in
regulating GVHD. Absence of STAT1 signaling in donor T cells
reduced experimental GVHD and resulted in reduced
expansion of donor T effector cells but caused an expansion
of donor regulatory T cells [49]. STAT1 deﬁciency in natural
regulatory T cells reduced their apoptosis but also facilitated
expansion of inducible regulatory T cells. Another recent
study demonstrated that absence of STAT3 in donor T cells
enhanced stability of natural donor regulatory T cells and
enhanced generation of induced regulatory T cells from naïve
alloreactive donor CD4þ T cells [50]. The generation of
induced regulatory T cells but not the presence of natural
regulatory T cells was critical for the protective effect of
absence of STAT3 signaling in donor T cells. Another study
showed that small molecule-mediated targeting of JAK3 in
donor T cells reduced GVHD [51]. These data suggest that
small molecules that can target selective JAK-STATmolecules
in donor Tcells could be effective inmitigating clinical GVHD.ACKNOWLEDGMENT
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